Kaplan Fox Encourages Corcept Therapeutics, Inc. (CORT) Investors to Inquire About Ongoing InvestigationNEW YORK, NY - February 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
Kaplan Fox Encourages Corcept Therapeutics, Inc. (CORT) Investors to Inquire About Ongoing InvestigationSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated (CORT)NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (
NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive.
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
INVESTOR ALERT: Securities Class Action Filed Against Corcept Therapeutics Incorporated – Investors Encouraged to Contact Kirby McInerney LLP
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (
NASDAQ:CORT) securities during the period of October 31, 2024 through December 30, 2025, inclusive (“the Class Period”).
Rosen Law Firm Urges Corcept Therapeutics Incorporated (NASDAQ: CORT) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated (
NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). Corcept is a pharmaceutical company.
CORCEPT THERAPEUTICS INCORPORATED (CORT) INVESTOR ALERT Investors With Large Losses in Corcept Therapeutics Incorporated Should Contact Bernstein Liebhard LLP To Discuss Their RightsNEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (
NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive.
CORT Investors Notified of Investigation Into Corcept Therapeutics, Inc. by Kaplan FoxSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
CORT Investors Notified of Investigation Into Corcept Therapeutics, Inc. by Kaplan FoxNEW YORK, NY - February 23, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
Corcept (CORT) Q4 Earnings: What To ExpectBiopharma company Corcept Therapeutics (
NASDAQ:CORT)
will be announcing earnings results this Tuesday afternoon. Here’s what to expect.
Kaplan Fox is Investigating Possible Securities Law Violations Against Corcept Therapeutics, Inc. (CORT)Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox is Investigating Possible Securities Law Violations Against Corcept Therapeutics, Inc. (CORT)NEW YORK, NY - February 21, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (
NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law ViolationsNEW YORK, NY - February 20, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals
Corcept Therapeutics Incorporated (
NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym® does not infringe two of Corcept’s patents concerning methods of safely co-administering Korlym and drugs that inhibit the CYP3A4 enzyme, including drugs that are commonly prescribed to patients with Cushing’s syndrome. The ruling affirms a December 2023 verdict by the Federal District Court for the District of New Jersey.
CORT ALERT: Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Possible Securities Law ViolationsNEW YORK, NY - February 19, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
CORT ALERT: Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Possible Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
CORCEPT THERAPEUTICS ALERT: Corcept Therapeutics, Inc. (CORT) are Encouraged to Contact Kaplan Fox Regarding Potential Securities Law ViolationsNEW YORK, NY - February 18, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Incorporated (
NASDAQ: CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
CORT SECURITIES INVESTIGATION: Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Potential Securities Law ViolationsNEW YORK, NY - February 17, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (
NASDAQ: CORT).
